Navigation Links
Myoderm Selects Tracie DiPasquale To Lead CentralSource
Date:1/8/2013

Norristown, PA (PRWEB) January 08, 2013

Myoderm, a global leader in sourcing commercial drugs for clinical trials, is pleased to announce that Tracie DiPasquale has joined the company as Director, CentralSource. She will work out of Myoderm’s US office.

Myoderm is fortunate to have someone with Tracie’s background and qualifications to direct CentralSource, the company’s turnkey sourcing, distribution, and management service that supplies individual sites directly on an as-needed basis. For over a decade, she managed business development efforts and implemented supply chain strategies for leading pharmaceutical firms, including Pfizer and Almac. Her diversified experience with both large and small pharmaceutical companies gives her the insight and flexibility to exceed clients’ needs.

A graduate of the University of Pittsburgh, with a B.Sc. degree in Natural Sciences and a minor in Biology, Tracie offers Myoderm customers a unique understanding of global clinical site drug supply management and oversight issues.

Mike Cohen, Managing Director of Myoderm, says, “Tracie’s experience from both the service and client sides gives her an invaluable perspective on sourcing issues and makes her a superb advocate for Myoderm clients.”

About Myoderm
Myoderm is a leader in the sourcing, distribution, and management of commercial pharmaceutical products and supplies for clinical trials and biosimilar research. The company’s clients span the globe and include biotech, CROs, clinical trial packagers, and the majority of the world’s top10 pharmaceutical companies. With its deep expertise, customized solutions, and commitment to personalized service, Myoderm provides the optimal drug supply solution for global clinical studies.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10292730.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. UCAN Selects Defran Systems to Support its Wide Range of Youth and Family Programs
2. President Obama selects Rutgers cell biologist Nihal Altan-Bonnet to receive prestigious award
3. The Gerontological Society of America Selects 2012 Fellows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... Doorknobs are for convenience, deadbolts are ... getting a guard dog or having an alarm system installed. But unless there is ... entry. Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX says: “In the ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... By scoring ... its ninth consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's ... top 1% of all charities reviewed by Charity Navigator and earns ANRF a spot ...
(Date:6/23/2017)... Va. (PRWEB) , ... June 23, 2017 , ... The ... the president's nominee for deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. ... Veterans Affairs. , Bowman brings an intimacy with the issues and challenges ...
(Date:6/23/2017)... New York, NY (PRWEB) , ... June 23, 2017 , ... ... prefer to watch it while others prefer to read it, and some people don't ... printed versus visual pornography. Here's what they found: , Erotic literature can give readers ...
(Date:6/23/2017)... D.C. (PRWEB) , ... June 23, 2017 , ... ... during cooking is essential, and two new videos highlight the importance of correctly ... Specialist Christine Bruhn, Ph.D., who has done extensive research on consumer food safety ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 2017 The Bio Supply Management Alliance (BSMA) ... Fremont and the Biomedical Manufacturing Network to ... California by providing a platform ... fostering workforce development. The primary focus of this alliance ... as well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... U.S. Food and Drug Administration (FDA) has notified the Company ... its Zhejiang, China manufacturing facility has ... successful clearance of the Warning Letter related to our ... measure of the progress we have made in our ongoing ...
(Date:6/11/2017)... INDIANAPOLIS , June 10, 2017  Eli Lilly and ... results from three Phase 3 studies of galcanezumab, an ... migraine, including late-breaking data on several key secondary endpoints ... Detailed results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) ... (AHS) annual scientific meeting in Boston ...
Breaking Medicine Technology: